Diabetes mellitus, together with its various complications, is becoming a serious threat to human health. Natural products are secondary metabolites widely distributed in plants, having a broad range of biological activities. The development of antidiabetic medication from natural products, especially those originating from plants with a traceable folk-usage history in treating diabetes, is receiving more attention. Many studies highlighted not only the benefits of natural flavonoids with hypoglycemic effects, but also their importance in the management of diabetic complications. This review describes selected natural flavonoids that have been validated for their hypoglycemic properties, together with their mechanisms of action. Also discussed are their activities in the treatment of diabetic complications demonstrated via laboratory diabetic animal models, in vitro and clinical trials using human subjects. Published papers from 2000 to date on flavonoids and diabetes were covered through accessing Web of Science and multiple databases for biomedical sciences. The major potential benefits of natural flavonoids discussed in this review clearly suggest that these substances are lead compounds with sufficient structural diversity of great importance in the antidiabetic drug developing process.
Diabetes mellitus is a metabolic disorder disease with hyperglycemia as its typical character. This hyperglycemia results in three classical symptoms of diabetes: polyuria, polydipsia and polyphagia. The World Health Organization divides diabetes mellitus into two main types: Type 1 and Type 2. Type 1 diabetes (T1B) results from an insulin production problem, which requires lifelong administration of insulin. Type 2 diabetes (T2B) is caused by the body's defect in insulin secretion, called insulin resistance. T2B comprises 90% of people with diabetes around the world, mainly due to obesity and physical inactivity [1] .
Data from the International Diabetic Federation (IDF) demonstrates that the number of people with diabetes in 2013 has reached 382 million, representing 5.4% of the world's population [2] . With 98.4 million adults with this disease, China has become the country with the largest population of diabetics in the world. According to the IDF, diabetes and its complications have a significant economic impact on medical expenditure, which already accounts for 5-18% of the total healthcare budget in many countries.
With a centuries-old history till now, humans use natural substances, mostly by means of a plant extract or a crude medical recipe, to cure diseases. Many of them serve as leads of important drugs that have become mainstays in modern therapy [3] . For example, among antidiabetic agents, metformin used for prediabetes and T2B, was originally isolated from Galega officinalis, a plant used in folk medicine [4] . Acarbose, the most widely used α-glucosidase inhibitor for the treatment of T2B, resulted from a screening, performed by Bayer AG, of natural products isolated from Actinomycetes species for inhibition of digestive enzymes [5] . Natural products are an abundant source for antidiabetic drug discovery despite the lack of content determination, quality and safety control. By following an integrated approach and using correct procedures, antidiabetic agents from medicinal plants especially used in folk medicine for diabetes treatment may provide an alternative to the classical drugs used (insulin and oral hypoglycemic agents), with few side effects and low cost for the maintenance of treatment [6] .
Flavonoids are a class of plant secondary metabolites with the backbone of flavone (2-phenylchromen-4-one). Important subgroups are flavanols, flavonols, flavones, isoflavones, flavanones, flavanonols and anthocyanins, which are defined by the functional groups attached to the basic flavonoid structure. They Action on islet β-cells and release of insulin from β-cells: When blood sugar concentration rises, β-cells of the endocrine pancreas release insulin, the hormone that controls the level of glucose, into the blood stream [9] . Decreased viability and dysfunction of pancreatic β-cells leads to the development of diabetes as a critical metabolic disorder.
Many flavonoids were proposed as potential antidiabetic agents because they exert multiple actions on islet β-cells. In this respect, the functions of flavonoids can be divided into (i) protection against β-cell damage [10] [11] [12] [13] [14] [15] [16] , (ii) increased proliferation of islet β-cells [17, 18] and (iii) preservation of insulin signaling by increased insulin secretion [19] [20] [21] .
Enhancement of glucose utilization in tissues and organs:
Glucose utilization involves cellular glucose transport, which is mediated by a family of facilitative glucose transporters (GLUTs) as solute carriers through a signaling pathway involving the insulin receptor tyrosine kinase [22] . In diabetes, this complex system of insulin-stimulated whole-body glucose utilization is impaired, probably because of defective GLUT-4 translocation and aberrant insulin signal transduction [23] .
It has been proven that several natural flavonoids affect this transduction and enhance the utilization of glucose, by their action on glucose transport [24] [25] [26] [27] [28] [29] [30] and insulin-receptor signaling [31] [32] [33] [34] [35] [36] [37] [38] .
Reduction of breakdown of glycogen:
In the course of consumption, glucose is phosphorylated to glucose-6-phosphate by glucokinase, followed by glycogen synthesis, glycolysis or triglyceride synthesis [39] . Insulin inhibits gluconeogenesis and glycogenolysis by its effect on regulating the transcription of genes encoding hepatic and muscular enzymes, such as phosphoenolpyruvate carboxykinase and glucose-6-phosphatase (G-6-Pase) [40] .
Flavonoids have been found to increase the glucokinase level, thus promoting glycogen synthesis [10, 41] , to reduce G-6-Pase and phosphoenolpyruvate carboxykinase gene expression, thus inhibiting gluconeogenesis or glycogenolysis [42] [43] [44] , or both [45] [46] [47] .
Inhibition of α-glucosidase to reduce intestinal glucose absorption: Carbohydrates are hydrolyzed to their corresponding monosaccharides by intestinal brush-border enzymes before absorption. Among these enzymes, α-glucosidase is the most important in carbohydrate digestion. Hence, α-glucosidase inhibitors reduce the impact of carbohydrates on blood sugar. Acarbose, an α-glucosidase inhibitor, can significantly decrease the Type 2 diabetics' fasting and postprandial blood glucose, glycosylated hemoglobin (HbA1c) and improve insulin sensitivity effectively [48, 49] .
Many flavonoids can be used as α-glucosidase inhibitors [50, [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] , and they can prevent the digestion of carbohydrates and delay glucose absorption. In addition, sucrase, maltase and α-amylase inhibitors [51, 61] also show hypoglycemic potential in the treatment of diabetes mellitus. inhibition of α-glucosidase [60] Quercetin
ZC:
inhibition of α-glucosidase [62] Abbreviations: G-6-Pase, glucose-6-phosphatase;
Natural flavonoids with antidiabetic activities reported in in vivo studies: Besides the studies on the mechanisms of action of flavonoids against diabetes, attention was also given to their activities in the treatment of experimental diabetic animals. New studies on natural flavonoid compounds with diverse skeletons and antidiabetic potential reported since 2000 to date are reviewed here, with the parameters tested ( Table 2) .
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In a study to investigate the effect of fisetin on streptozotocin (STZ)-induced diabetic rats, treatment with this flavonol improved hyperglycemia and oxidative stress [63] . In a similar diabetic model, quercetin administration resulted in a reduction of hyperglycemia, hyperlipidemia and oxidative stress. Moreover, an increase in serum insulin levels and a reestablishment of glucose tolerance curves were observed as well [10] [11] [12] .
In a large prospective study across European countries, the relationship between individual flavanol and flavonol intakes and risk of developing T2B was investigated. The intakes of flavan-3-ol monomers, proanthocyanidin dimers and myricetin were found to be associated with a lower incidence of T2B, highlighting the importance of the assessment of the flavonoid subclasses [64] .
The flavone eupatilin, isolated from Artemisia princeps, was used to study the effect on C57BL/KsJ-db/db diabetic mice, a model for diabetic dyslipidemia. It was demonstrated that supplementation with eupatilin significantly lowered the fasting blood glucose concentration, HbA1c and plasma glucagon levels, while it simultaneously increased the hepatic glycogen content, plasma insulin and adiponectin levels [20] .
Wogonin, also a flavone, was isolated from Scutellaria baicalensis. Treatment with wogonin in db/db mice resulted in a remarkable weight gain and improved glucose tolerance. The beneficial effects of wogonin on diabetes and lipid metabolism were demonstrated through peroxisome proliferator-activated receptor alpha (PPARα) and AMP-activated protein kinase (AMPK) activation [65] .
Two new flavones, 5,7-dihydroxy-6,8-dimethyl-4'-methoxyflavone and 8-(2-hydroxypropan-2-yl)-5-hydroxy-7-methoxy-6-methyl-4'-methoxy-flavone were isolated from Callistemon lanceolatus. Further investigation showed that they had a significant blood glucose lowering effect in STZ-induced diabetic rats [66] .
Genistein and daidzein, the major isoflavones of soybean (Glycine max), were found to prevent diabetes onset and to preserve β-cells of the pancreas in non-obese diabetic mice, a model of the onset of T1B [67] . Another study showed that genistein increased the plasma insulin level while decreasing the HbA1c level in STZ-induced diabetic rats. Antioxidant enzyme activities were observed as well [42] . Additionally, in a survey of postmenopausal women with metabolic syndrome, treatment with genistein for one year modulated risk for both diabetes and cardiovascular disease [68] . Besides, biochanin A, another soy isoflavone, was found to be antihyperglycemic in STZ-induced diabetic rats [69] . These results again suggested isoflavone's beneficial potential for diabetes.
Glabridin is an isoflavane from licorice. In STZ-induced diabetic mice, treatment with glabridin resulted in a significant increase of glucose tolerance and superoxide dismutase (SOD) activities while decrease of fasting blood glucose levels, suggesting glabridin as a potential hypoglycemic agent [70] .
Naringenin, which is a citrus-derived flavanone, displayed both lipid-lowering and insulin-like properties. In a model of dietinduced insulin resistance, the addition of naringenin could prevent dyslipidemia, normalize blood glucose, plasma insulin and glucose tolerance [71] . In another study, the antihyperglycemic and antioxidant effects of naringenin in STZ-nicotinamide-induced diabetic rats were evaluated, suggesting its potential on metabolic syndrome [72] .
Phloridzin, a dihydrochalcone, is naturally occurring in apples. Diets containing phloridzin showed anti-hyperglycemia activity. However, unlike quercetin, it failed to improve hypoinsulinemia and tissue lipid peroxidation in STZ-induced diabetic mice [73] .
Two chalcones, 4-hydroxyderricin and xanthoangelol were isolated from Angelica keiskei. Basal diets containing 4-hydroxyderricin and xanthoangelol both decreased blood glucose levels of KK-Ay mice, an animal model of metabolic syndrome. In a glucose uptake assay, 4-hydroxyderricin showed stronger activity, compared with xanthoangelol [74] . Isoliquiritigenin is also a chalcone found in Glycyrrhiza glabra. In a hypoglycemic screening test, isoliquiritigenin and its derivatives were found to be effective for lowering blood glucose and ameliorating oral glucose tolerance in normal Swiss albino mice [75] .
Licochalcone E, a retrochalcone isolated from Glycyrrhiza inflata, was proven to be effective in diabetic hyperglycemia and hyperlipidemia. Additionally, treatment with licochalcone E also increased the levels of PPARγ expression, suggesting the mechanism of stimulation of Akt signals [76] .
Green tea is a significant source of typical flavonoids called catechins, including (-)-epigallocatechin gallate (EGCG), (-)-epigallocatechin, (-)-epicatechin gallate and (-)-epicatechin. An injection of EGCG produced a significant decrease in serum glucose levels, food intake and body weight in Sprague Dawley rats, as well as in lean and obese Zucker rats [77] . Additionally, EGCG showed a beneficial effect on glucose metabolism in high-fat diet-induced mice. An improvement of insulin sensitivity and endothelial function was observed as well [78] .
Besides, (-)-epicatechin, the active constituent in the extract of Pterocarpus marsupium bark, which is traditionally used in Indian folk medicine to treat diabetes, also showed significant hypoglycemic effects [79] . In another study searching for T1B beneficial agents, epicatechin was discovered to increase plasma insulin, but decrease HbA1c levels. Improved pancreatic islet mass and insulitis were seen as well, demonstrating that epicatechin is a flavonoid capable of preventing T1B [80] .
Anthocyanins, with their aglycone derivatives, called anthocyanidins, belong to the flavonoids. Of these groups, pelargonidin, together with pelargonidin-3-O-rhamnoside and pelargonidin-3-galactoside, displayed significant hypoglycemic effects in diabetic rats. Moreover, pelargonidin treatment was found to decrease blood glucose, normalize glucose tolerance, improve serum insulin levels and alleviate oxidative damage in STZ-induced diabetic rats [81] .
Silybinin is the major flavonolignan in the extracts of milk thistle seed, Silybum marianum. In patients with T2B and associated chronic liver disease, a better glucose and lipid metabolism was observed after treatment with a silybinin-β-cyclodextrin complex agent. Moreover, insulin sensitivity was improved after the use of silybinin in T2B patients [82] .
In an investigation of apigenin-6-C-(2"-O-α-L-rhamnopyranosyl)-β-L-fucopyranoside, which was isolated from Averrhoa carambola leaves, an acute lowering effect on blood glucose was observed in hyperglycemic rats. The compound could also significantly stimulate 14 C-glucose uptake and glucose-induced insulin secretion [83] . Apigenin-6-C-β-L-fucopyranoside, another natural flavonoid with the same aglycone from this plant, showed a similar effect in hyperglycemic rats [84] . Diosmetin-7-O-β-L-arabinofuranosyl (1''→2')-β-D-apiofuranoside and diosmetin-7-O-β-D-apiofuranoside, were isolated from date fruits epicarp. In their biological assessment, both flavonoids showed marked improvement on serum glucose, liver functions and oxidative stress [85] .
Naringin, a naringenin glycoside, and hesperidin, also citrus-derived bioflavanones, both significantly decreased blood glucose and elevated plasma insulin in C57BL/KsJ-db/db mice, probably via hepatic glucose-regulating enzymes [46] . Besides, hesperidin also displayed a preventive action against diabetic embryopathies [86] .
Water decoction of the plant Cecropia obtusifolia is traditionally used for the treatment of T2B in Mexico. Bioassay-guided isolation of the active components from this plant led to the identification of isoorientin, a flavonoid. Further pharmacological tests showed that isoorientin exhibited a significant hypoglycemic effect comparable with that of glibenclamide, an antidiabetic drug stimulating insulin release in STZ-induced diabetic rats [87] .
Rutin, a glycoside of quercetin, was found to be antihyperglycemic in STZ-induced diabetic Wistar rats. Treatment of diabetic rats with rutin also resulted in a prevention of oxidative stress, since a decrease of thiobarbituric acid reactive substances (TBARS) and lipid hydroperoxides and an increase of non-enzymatic antioxidants were observed [88] .
Kaempferol-3,7-O-α-dirhamnoside (kaempferitrin), isolated from Bauhinia forficata leaves, was found to decrease serum glucose levels significantly both in normal and alloxan-induced diabetic rats. However, kaempferitrin failed to change the glucose tolerance curve during the time course [89] . In another study, gossypin, a natural pentahydroxyflavone glucoside isolated from the flowers of Hibiscus vitifolius, was proven to display remarkable antihyperglycemic activity in STZ-induced diabetic rats [90] . [79] ; plasma insulin and pancreatic islet mass (↑), HbA1c (↓) [80] Chen et al. glucose tolerance, plasma protein and urea levels (→), blood glucose, HbA1c (↓), glycogen content in liver and muscles, plasma insulin, hemoglobin levels (↑) [90] Abbreviations: HbA1c, glycated hemoglobin; GSH, glutathione; TG, triglyceride; MDA, malondialdehyde; NO, nitric oxide; T2B, type 2 diabetes; PPAR, peroxisome proliferator-activated receptor; AMPK, AMP-activated protein kinase; TC, total cholesterol; SOD, superoxide dismutase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TBARS, thiobarbituric acid reactive substances; GSH-PX, glutathione peroxidase; Symbol meaning: ↑, increase; ↓, decrease; →, normalize Studies on flavonoids used for the treatment of diabetic complications: Diabetes needs careful management otherwise it can lead to various complications such as cardiovascular disease, kidney failure, nerve damage and blindness. The beneficial effects of flavonoids are numerous, involved in battling many types of diabetic complications. Their specific bioactivities on different diabetic complications, with the parameters tested, are stated in Table 3 .
Treatment of diabetes-related cardiovascular disease: Diabetes has become a major risk factor for cardiovascular disease (CVD), and in turn, CVD is the main cause of death in people with diabetes [91] . More and more epidemiological studies have suggested an inverse association between the dietary intake of flavonoids and the risk of vascular disease [92] .
For those drugs with poor solubility, cyclodextrins can be used in pharmaceutical preparations to increase the bioavailability. In a study of the effects on left ventricle dysfunction in STZ-induced diabetic rats, β-cyclodextrin complex of quercetin decreased the degree of myocardial necrosis and the myocardial fructose levels, demonstrating that quercetin had a cardioprotective activity [93] .
In another study, treatment with the phytoestrogenic isoflavones genistein and daidzein effectively improved glucose toxicityinduced cardiac mechanical malfunction in ventricular myocytes [94] . Astilbin, a flavonoid isolated from Smilax china, together with luteolin, were both found to display anti-myocardial ischemia and reperfusion injury effect [95, 96] . Besides, luteolin was found to be protective against T1B cardiomyopathy by attenuation of myocardial oxidative stress [97] . Naringin was proven to be effective in the improvement of the atherogenic index in T1B [98] . All these results suggest that the flavonoids-related preparations have a therapeutic role against diabetes-associated cardiac defects.
Treatment of diabetic nephropathy:
Diabetic nephropathy is one of the most serious complications in diabetes mellitus, and it could cause end-stage renal failure among patients undergoing chronic hemodialysis therapy [99] . Together with a good hypoglycemic activity, flavonoids could be used to prevent the development and progression of nephropathy.
The flavonoid mixture silymarin was tested for its effect on oxidative stress and renal tissue morphology in alloxan-induced diabetic rats. Tissue damage caused by alloxan was prevented by silymarin treatment and the activity and gene expression of three antioxidant enzymes were restored after the treatment with silymarin [100] . In another study, the protective effect of silybin against high glucose-induced podocyte injury was observed demonstrating its utility against diabetic nephropathy [101] .
Supplementation of green tea catechin recovered the destroyed balance between prostacyclin and thromboxane A2, an index of kidney function, in the kidney microsomes of STZ-induced diabetic rats. Catechin also adjusted the kidney TBARS content, an index of lipid peroxidation, to the normal level [102, 103] . On the other hand, treatment with tea catechin significantly reduced albuminuria in diabetic rats. Moreover, it helped to normalize glomerular hypertrophy, interstitial fibrosis as well as endothelial function [104, 105] . These results suggest that tea catechin can contribute to the prevention of diabetic kidney failure.
In a study of EGCG, treated rats with subtotal nephrectomy and STZ injection showed decreased hyperglycemia, suppressed proteinuria and lipid peroxidation. These results proved EGCG's Flavonoids in the treatment of diabetes Natural Product Communications Vol. 10 (1) 2015 193 beneficial effect on abnormal glucose metabolism-associated renal damage [106] .
Another study proved that breviscapine, a flavonoid isolated from the Chinese herb Erigeron breviscapus, showed a renoprotective effect in STZ-induced diabetic rats through suppression of renal macrophage recruitment [107] . Besides, the protective effects of genistein and naringenin in diabetes-induced renal damage were established through regulation of oxidative stress, fibrosis and inflammation [108, 109] . 
Treatment of oxidative stress-associated diabetic complications:
Diabetes is closely associated with oxidative stress, by which excessive free radicals are produced, resulting in further acceleration of diabetic complications [110] . Flavonoids are wellknown for their function as natural antioxidant agents by scavenging reactive oxygen species, by virtue of the number and arrangement of their phenolic hydroxyl groups attached to aromatic ring structures [111] . Therefore, natural flavonoids are helpful in many oxidative stress-related diabetic complications such as diabetic neuropathic pain, renal and liver damage.
In a study of the evaluation of diabetic peripheral neuropathy, the flavonoid baicalein was proven to reverse nerve conduction deficit and small sensory nerve fiber dysfunction through inhibition of oxidative/nitrosative stress [112] . Besides, diosmin, a citrus flavonoid, was found to act against streptozotocin-nicotinamide generated oxidative stress. Beneficial signs in preventing the progression of diabetic neuropathy were observed as well [113, 114] . Another report showed that quercetin significantly decreased oxidative stress and renal dysfunction in STZ-injected rats [115] . Additionally, the protective and regulatory effects of silymarin were investigated, in which silymarin normalized both the antioxidant status and the expression of cytochrome P450 and glutathione peroxidase [116] . Besides, treatment with rutin adjusted the antioxidant status of diabetic rats by decreasing lipid peroxidation products and by increasing enzymatic and non-enzymatic antioxidants [117] . These findings suggest that the protective role of flavonoids on diabetic organs damage is probably materialized through their anti-oxidative action.
Furthermore, recent studies have proven that treatment with quercetin and morin, as well as naringin, effectively regulated apoptosis through intervention in oxidative stress, suggesting the linkage between flavonoids and high-glucose induced apoptosis [118] [119] [120] . 
Treatment of diabetes-related hyperlipidemia:
Hyperlipidemia is often seen in diabetes. Flavonoids are found to have not only antidiabetic activity but also a hypolipidemia effect.
Rutin was found to have a beneficial effect on lipids, lipoproteins, lipid-metabolizing enzymes and glycoproteins [121] . Apigenin was demonstrated to alleviate hyperlipidemia and atherosclerosis in diabetes by increasing phosphorylation of hepatocellular AMPK, which plays an important role in the pathogenesis of diabetic hyperlipidemia [122] .
Treatment of diabetic complications associated with advanced glycation end-products: Advanced glycation end-products (AGEs) are a diverse class of biomolecules resulting from non-enzymatic glycation of amino acids, peptides, proteins or amines with reducing sugars, such as glucose and fructose, or its autooxidation products. They are specifically the result of the Maillard reaction [123] . The AGEs play an important role in the development of diabetic complications, such as neuropathy, retinopathy and nephropathy [124] . Flavonoids have the proven ability to inhibit the formation of AGEs.
In a study of the protective potential against protein damage of four flavonoids, isoquercetin and hyperin exerted a stronger inhibitory activity against the formation of AGEs in vitro. The activities were more potent than that of aminoguanidine, a known glycation inhibitor [59] . In another study, isoquercetin with two other flavonol glycosides, quercetin-3-O-α-L-arabinopyranosyl-(1→2)-β-D-glucopyranoside and kaempferol-3-O-β-D-glucopyranoside (astragalin), isolated from the leaves of Eucommia ulmoides (Eucommiaceae), were demonstrated as glycation inhibitors [125] .
The ethanolic extract of Vaccinium vitis-idaea (Ericaceae) berries was tested for inhibition of AGE formation. Following HPLC-MS analysis, seven flavonoids were identified, of which quercetin, (+)-catechin, hyperin and cyanidin-3-O-galactoside showed significant antiglycation activities [126] . In another study, the bioguided fractionation of Calophyllum flavoramulum afforded a biflavonoid named amentoflavone, and it was demonstrated as a natural inhibitor of AGEs [127] . These results suggest the potential of flavonoid-related preparations for the treatment of AGEs-associated diabetic complications. Diabetic retinopathy (damage to the retina) is also a type of complication from diabetes mellitus, which induces blindness at the end. Treatment with genistein was found to normalize the retinal vascular permeability in STZ-induced diabetic rats [128] . In three Breviscapine diabetic nephropathy kidney weight, urinary albumin excretion rate, tubulointerstitial injury, MDA (↓) SOD, CAT and GSH-PX (↑) [107] Catechins diabetic nephropathy prostacyclin / thromboxane A2 ratio (→), TBARS (↓) [102, 103] ; urinary albumin excretion rate (↓), interstitial fibrosis area (→) [104, 105] Daidzein cardiovascular disease mechanical malfunction in ventricular myocytes (↓) [94] Genistein cardiovascular disease diabetic retinopathy diabetic nephropathy mechanical malfunction in ventricular myocytes (↓) [94] ; retinal vascular permeability, retinal albumin, phosphotyrosine, proliferating cell nuclear antigen (↓) [128] ; MDA, blood urea nitrogen, plasma creatinine (↓) , SOD, GSH-PX (↑) [108] Hesperetin diabetic retinopathy GSH levels, antioxidant enzyme activity (→), cytokines level, caspase-3, glial fibrillary acidic protein and aquaporin-4 expression (↓) [ oxidative stress and choline esterase activity (→) [132] ; TG, TC, MDA, LDL, creatine kinase, lactate dehydrogenase, myocardial connective tissue growth factor (↓), SOD, HDL, Akt phosphorylation (↑) [97] ; LDH release, incidence of arrhythmia, myocardial infarct size, myocardial apoptotic death (↓), left ventricular ejection fraction (↑) [96] Quercetin cardiovascular disease AGE formation depression body mass, TG, cholesterol, myocardial fructose (↓) [93] ; inhibition of glycation [126] ; immobility period (↓) [136] 
inhibition of glycation [125] Diosmin diabetic neuropathy MDA and nitric oxide levels (↓), GSH (↑) SOD activity, thermal hyperalgesia, cold allodynia and walking function (→) [113, 114] Rutin hyperlipidemia oxidative stress-related diseases cholesterol, TG, free fatty acids, phospholipids, LDL-cholesterol, very LDL-cholesterol, HMG-CoA reductase, glycoproteins, TBARS, HP (↓) LPL, LCAT, HDL-cholesterol (↑) [121] ; GSH, Vitamin C, Vitamin E, SOD, CAT, GSH-PX (↑) [117] Silymarin diabetic nephropathy oxidative stress-related diseases SOD, GSH, CAT (→) [100] ; MDA, NO (↓), total thiol molecular (↑), cytochrome P450 3A2, GSH-PX (→) [116] Sylibin diabetic nephropathy oxidative stress and podocyte injury (→) [101] Abbreviations: TC, total cholesterol; TBARS, thiobarbituric acid reactive substances; AMPK, AMP-activated protein kinase; ACC, acetyl-CoA carboxylase; MDA, malondialdehyde; SOD, superoxide dismutase; CAT, catalase; GSH-PX, glutathione peroxidase; GSH, glutathione; ALP, alkaline phosphatase; TG, triglyceride; LDL, low-density lipoprotein; HDL, high-density lipoprotein; Akt, protein kinase B; LDH, lactate dehydrogenase; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; HP, hydroperoxides; LPL, lipoprotein lipase; LCAT, lecithin-cholesterol acyltransferase; NO, nitric oxide; Symbol meaning: ↑, increase; ↓, decrease; →, normalize similar retinal oxidative stress and neuroinflammation studies, hesperetin, hesperidin and eriodictyol were all demonstrated to be effective for the prevention of diabetic retinopathy [129] [130] [131] .
Diabetes can cause cognitive decline, a dysfunction of the central nervous system. Luteolin was proven to be beneficial against cognitive dysfunction in STZ-induced diabetic rats, by improvement of neuronal injury and cognitive performance [132] . Furthermore, pentamethylquercetin, naringenin and cyanidin-3-glucoside were all demonstrated to be effective in the prevention of cognitive dysfunction in diabetes [133] [134] [135] .
Diabetes also causes depression, along with the inefficient plasma glucose control and increased risk of diabetic complications. Quercetin showed a potential in therapy for depression associated with diabetes. It markedly reduced the immobility period in STZinduced diabetic mice, compared with that of fluoxetine and imipramine, the classical antidepressants [136] .
Osteopenia (lowered bone mineral density) is also a diabetic complication. Myricetin displayed protective effects on 2-deoxy-Dribose-induced cytotoxicity in osteoblastic MC3T3-E1 cells and osteoblast dysfunction [137] . Similar activities were found after treatment with both kaempferol [138] and glabridin [139] . In another study, the protective effect of puerarin on osteoporosis was proven via its inhibition of caspase-3 expression [140] . These results suggest the benefits of flavonoids in diabetes-related bone diseases.
In another study, the consumption of xanthohumol in STZ-induced diabetic rats showed modulation on angiogenesis, inflammation and oxidative stress, suggesting its potential on neovascularization control and diabetic wound-healing improvement [141] . Besides, cyanidin-3-O-β-D-glucoside was proven to be beneficial in endothelial repair [142] , while genistein accelerated wound healing and improved wound angiogenesis through attenuating oxidative stress [143] , suggesting their utility in diabetic vascular complications. Structure-activity relationship of flavonoids as promising antidiabetic agents: Flavonoids exhibit multiple biological activities, such as antiviral, antiinflammatory, antiproliferative, anticancer and vasodilating actions, attracting the interest of scientists. Moreover, flavonoids are well proven to possess the ability to reduce free radical formation and to scavenge free radicals as natural antioxidants [144] , which could be considered as leads of choice in diabetes treatment [145] . More and more flavonoids have been demonstrated to be active on various biological targets for the treatment of diabetes and some structure-activity relationships are summarized in this part. The protective effects of flavonoids in diabetes as antioxidants are often ascribed to their capacity to scavenge free radicals and to activate antioxidant enzymes. In a study to evaluate the effects of quercetin and chrysin in alloxan-induced diabetic rats, the positive requirements for antioxidant activity of flavonoids were the presence of an ortho 3',4'-dihydroxy substitution on the B ring and the 3-OH moiety in the C ring [146] . The C2-C3 double bond was beneficial for activity as well [147] . Besides, 5-and 7-OH substituents together with 4-oxo groups could enhance the scavenger activity [148] , while glycosylation and methylation at position C-3 attenuated the ability to the contrary [149, 150] .
Flavonoids act also as remarkable aldose reductase (AR) inhibitors, which is promising for the prevention of diabetic complications. In a screening of 35 flavonoid derivatives as AR inhibitors, 5,7-dihydroxy groups in the A ring and ortho-dihydroxy substitution in the B ring seemed beneficial for the activity [151] . This conclusion was supported by Patra upon application of a quantitative structureactivity relationship methodology. Besides, it was predicted that flavonoids methoxylated on position C-3 would have strong AR activity [152] .
In a structure-activity relationship evaluation of natural flavonoids from Acanthopanax senticosus as α-glucosidase inhibitors, quercetin was found to be the most potent inhibitor when compared with its glycosides [153] . This result was in accordance with the work by Wang, in which it was concluded that the hydroxyl group at position C-3 in the C-ring and a number of hydroxyl groups attached to the B-ring played important roles in the inhibition activity [51] . However, two rhamnosyl moieties in kaempferitrin, as flavonoid glycoside, were proven to be essential for enhancement of the activity of 6-phosphofructo-1-kinase, an important enzyme involved in glucose utilization [154] . In addition, the presence of 3',4'-dihydroxy substitution and a C2-C3 double bond were demonstrated as crucial factors for the recognition and binding of glycogen phosphorylase, another important enzyme in glycogenolysis [155] .
Protein tyrosine phosphatase 1B (PTP1B), a promising target for the treatment of T2B, is considered to be a negative regulator of insulin receptor signaling. To determine the biological activities, both 5,7-dihydroxyflavanone and 2,4,6-trihydroxychalcone derivatives were synthesized and evaluated as novel PTP1B inhibitors. It was concluded that substitution with electron-withdrawing groups or an increase of the lipophilicity of the B ring enhanced inhibitory potency [156] . Increasing the number of hydroxyl groups on the A ring improved PTP1B inhibition [157] . Another study pointed out that isoprenylation of ring A or introduction of methoxy groups on ring B played an important role for the activity [158] .
Recently, it is believed that dual PPAR α and γ agonists targeting hyperglycemia and insulin resistance may be effective in treatment of T2B. A systematic structure-driven design based on flavonoid derivatives led to a conclusion that derivatives with the 7-hydroxy substituent, H-bond acceptors at the 3' or 4' position and a methoxy group at 3' or 3' and 5' position are selective for both PPAR α and γ, respectively [159] .
Conclusion and further perspectives: As the incidence of diabetic patients around the world continues to rise, and due to the complexity and diversity of the disease etiology, together with its multiple complications, medicinal researchers have increasing responsibilities to seek effective drugs for the treatment of diabetes mellitus [160] . Natural products and their derivatives have been among the most productive source of bioactive molecules in drug discovery [161] . The contribution of natural products to the development of antidiabetic agents is clearly evident, as we discussed at the beginning. Flavonoids are a large group of natural products and more than 10,000 different flavonoids from widespread plant sources have been reported and, with each year, hundreds of newly identified flavonoids are recorded [162] .
The major potential benefits of natural flavonoids discussed in this review clearly demonstrate that these substances represent remarkable lead compounds with a diversity of molecular structure and biological activity, in relation to the antidiabetic drug discovery process. Although considerable scientific progress has been made, especially over the past 10 years in unraveling the effect of flavonoids on diabetes, diabetic complications and their mechanism of action, the pharmacokinetic factors including the absorption, biotransformation, metabolism and toxicological aspects of flavonoids will have to be further investigated. Based on current studies of absorption and metabolism confined to a select group of dietary flavonoids, it is understood that flavonoid absorption is influenced by their chemical structure upon consumption [150] . Other investigations carefully demonstrated that flavonoid aglycones, which are hydrophobic in nature, are absorbed by passive diffusion whereas some hydrophilic glycosides can be transported by their interaction with sugar transporter-1 or specific active enzymes such as lactase-phloridzin hydrolase and cytosolic β-glucosidase [163] . After being absorbed, the flavonoids can be metabolized in pathways of methylation, sulfation and glucuronidation via corresponding enzymes located in the intestine, liver and kidney [164] . A series of hydroxylation, O-methylation, cleavage of the heterocycle, deglycosylation and scission of polymeric species into monomeric units during the flavonoid metabolism are shown as well. Nevertheless, various steps in the flavonoid-signaling network based on the complex mechanism of insulin action are still missing.
Although this review focuses on the pure natural flavonoids, a large number of plant extracts have been found to possess gratifying effects for the treatment of diabetes mellitus. Unlike a single chemical entity aimed at a specific single target, multi-flavonoidrich plant extracts managed to alleviate the disorder of diabetes mellitus, probably through an integrated effect upon multi-target sites. Flavonoids are very common in several comestible fruits and vegetables as part of our daily food consumption [165] . There is no doubt that plant extracts should be viewed as a potential complementary treatment for diabetes.
Diabetes mellitus firstly develops diabetic complications if the blood glucose is out of control. The evidence from published literature demonstrates that some flavonoids, such as quercetin and rutin, show multifunctional health benefits in diabetes and its complications due to their action on many targets with high affinity. Flavonoids, as an important class of natural products with high pharmacological activities, provide new insights into the potential role of lead compounds in diabetes treatment. In fact, several natural flavonoids, acting as attractive glucosidase, PTP1B or dipeptidyl peptidase-4 inhibitors have been proposed as potential antidiabetic drugs, since those inhibitors are closely involved in the biological process of diabetes [166] [167] [168] . A brief comment on relationships between flavonoid structure and biological activity involved in potential targets of diabetic pathophysiology is given, and this, together with the considerable antidiabetic flavonoid agents selected in this review, should help to provide leads to the ultimate goal of developing new, more efficient, therapeutic drugs for the treatment of diabetes mellitus and its complications, in spite of the fact that more clinical and experimental studies are obviously needed.
